
Vertex just got a bigger CASGEVY market, and Wall Street may still be underestimating it
Vertex’s CASGEVY expansion to patients as young as 2 looks like a real commercial runway extension, not a cosmetic label update. With elite margins, strong growth, and a TickerSpark Score of 89, the stock still looks built for more than a one-day pop.










